Enveric Biosciences Inc reports results for the quarter ended in December - Earnings Summary

Enveric Biosciences

29/03/2024 21:01

* Enveric Biosciences Inc  ENVB.OQ  reported a quarterly
adjusted
loss of $1.47​​ per share for the quarter ended in December. 
The mean expectation of three analysts for the quarter was for a
loss of $1.54 per share. Wall Street expected results to range
from $-1.59 to $-1.50 per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Enveric Biosciences Inc's reported EPS for the quarter was
a
loss of $1.47​.
    * The company reported a quarterly loss of $3.44 million.
    * Enveric Biosciences Inc shares had fallen by 21.5% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 2.8%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Enveric
Biosciences Inc is $10.00 
This summary was machine generated from LSEG data March 29 at
09:01 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -1.54          -1.47          Beat
 Sep. 30 2023      -2.09          -1.30          Beat
 Jun. 30 2023      -0.65          -3.04          Missed